Norwegian version of this page

Pancreatic cancer biology and therapeutics

Pancreatic cancer is the fourth leading cause of cancer-related death in the Western world and it is predicted to rank second by 2030. The prognosis of pancreatic cancer is grim, mainly due to late diagnosis and profound chemoresistance. 

About the project

Pancreatic cancer has an unusually prominent stroma, which plays a central role in the tumours´s chemoresistance. Tumour stroma and chemoresistance, and the multifarious links between them, stand in the focus of our research.  

Our research projects cover in vitro and ex vivo approaches as well as the characterization of human tumour tissue.

Parts of the project that focus on metabolomics, tumour heterogeneity, and chemosensitivity are included in the research portfolio of The Norwegian Cancer Society’s Group of Expertise for Pancreatic Cancer.

This national consortium consists of research groups with clinical and lab-based expertise in pancreatic cancer research. The groups are affiliated to the University of Oslo, Oslo University Hospital, University of Bergen, and Stavanger University Hospital.


  1. Stromabiology and cancer-stroma interactions
  2. Metabolomics and chemosensitivity
  3. Effect of neoadjuvant treatment 
  4. Stromal heterogeneity and treatment-induced changes
  5. Precision-cut ex vivo culture system



  • Knut Jørgen Labori, Oslo University Hospital
  • Stein Kaasa, Dept. of Oncology, University of Oslo and Oslo University Hospital

  • Lovise Mæhle, Dept. of Medical Genetics, Oslo University Hospital

  • Elin Kure, Oslo University Hospital
  • Kjetil Tasken, Institute of Cancer Research, University of Oslo

  • Oddmund Nordgård, Dept. of Haemtaology and Oncology, Stavanger University Hospital

  • Anders Molven, Depts. of Clinical Medicine, Biomedicine and Clinical Science, University of Bergen


  • Matthias Löhr, CLINTEC, Karolinska Institute, Sweeden
  • Mikael Björnstedt, Karolinska Institute, Sweeden
  • Lars O. Dragsted, University of Copenhagen, Denmark
  • Jan Borén, University of Gothenburg, Sweeden
  • Jérôme Cros, Hôpital Beaujon, Paris, France
  • Marco Del Chiaro, University of Colorado, Denver, USA
Published Apr. 10, 2019 10:33 AM - Last modified Mar. 4, 2020 11:20 AM


Group leader


Detailed list of participants